Disparities in Excess Blood Pressure Across the U.S. Associated With Air Pollution Exceeding WHO Guidelines | JACC: Advances jacc.org/doi/10.1016/j.…

Out in European Society of Cardiology Journals, led by Dr Chen, we developed a novel pipeline to examine expomic features from street view images and show that they explain significant variation of CAD prevalence in the US. Paving the way for contextualizing the enviroment for CVD shorturl.at/biFL9

Excited for #ACC24? Visit NasirLab Houston Methodist CV prevention team presentations & share ur feedback -Burden, variability and national/health system impact of CV metabolic risk -CV impact of exposome measurements - Insights on Cardiorhum & novel atheromeasurement in gen pop

If you are in Atlanta for #ACC24, join the phenomenal CV prevention team Houston Methodist CV as they present their work and share the latest insights in cardiovascular prevention. Khurram Nasir Sadeer Al-Kindi, MD

Dr. Izza Shahid discussed the demographics and regional patterns of atherosclerotic cardiovascular disease-related mortality among young adults in the U.S. #ACC24 #CardioEd #CardioTwitter

Is CAC=0 enough to assess for CAD in a young symptomatic woman? Khurram Nasir debates in favor of the prognostic utility of #powerofzero #ACC24

Dr. Ryan Chang shares insights at #ACC24 on the relationship between body mass index and per capita medical expenditures in U.S. adults with ASCVD who might be eligible for semaglutide. #MedicalResearch #Cardiology #ASCVD

Dr. Izza Shahid unveils a poster at #ACC24 highlighting financial toxicity in individuals eligible for semaglutide within a U.S. representative population with established atherosclerotic cardiovascular disease. #MedicalResearch #Cardiology #ASCVD

Dr. Izza Shahid presents at #ACC24 on cost-related medical non-adherence in semaglutide-eligible U.S. adults with atherosclerotic cardiovascular disease, offering insights for the nationally representative population. #MedicalResearch #Cardiology #ASCVD

Dr. Mohamad Taha discusses at #ACC24 the clinical and sociodemographic variations in mortality risk by obesity class among patients eligible for semaglutide cardiovascular outcome trials, based on a national population study. #MedicalResearch #Cardiology #ObesityAwareness

Dr. Budhaditya Bose shares findings at #ACC24 on identifying phenotype clusters among ASCVD patients eligible for semaglutide therapy within a large integrated health system. #MedicalResearch #Cardiology #ASCVD

Dr. Helene DiGregorio discusses at #ACC24 prevalence of cardiometabolic risk factors in patients with vs without rheumatologic disease, drawing insights from Houston Methodist cv disease learning health system registry. #MedicalResearch #Cardiology #RheumatologicDisease

SDOH Q3/4 & class 3 obesity have 3.5 fold inc risk of premature mortality. Jerrin Philip presenting on association between SDOH quartile per obesity class and mortality: a double jeopardy at #ACC24 Khurram Nasir Sadeer Al-Kindi, MD

Financial toxicity in pts eligible for Semaglutide in the US: Izza Shahid presents 2 posters regarding predictors of FT and cost-related medication non adherence in a nationally representative cohort. Khurram Nasir Sadeer Al-Kindi, MD

Join us at C3PH & NasirLab We're looking for a proactive Postdoc/Data Scientist to explore nexus of big data/AI in exposome & biology for cardiometabolic/atherosclerotic disease research Dive into large national datasets/health system registries with us! Details 👇